Yuhan Corporation Receives Approval for Phase 1 Clinical Trial of Gaucher Disease Treatment Yuhan Corporation has taken its first step towards developing a treatment for a rare disease. The company…

A study demonstrating the superior efficacy of the combination therapy of Yuhan Corporation's non-small cell lung cancer (NSCLC) treatment, Leclaza (ingredient name: lazertinib), over the monotherapy…

Ahn Jae-Yong, CEO of SK Bioscience, highlighted the strategic importance of acquiring German contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO)…